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Simple Summary: Radiofrequency ablation (RFA) is a curative treatment for early-stage
hepatocellular carcinoma (HCC) ineligible for surgery or liver transplantation. However,
trans-arterial chemoembolization (TACE) might be an alternative when RFA is contraindicated
due to structural problems. Among treatment-naive HCC patients fulfilling the Milan
criteria who underwent RFA (n = 136) or TACE (n = 268), complete response (CR) and 5-year
recurrence-free survival (RFS) rates were higher in the RFA group than in the TACE group
(94.1% vs. 71.6% and 35.8% vs. 17.0%, respectively; both p < 0.001), whereas 5-year overall
survival (OS) rates were not significantly different (65.5% vs. 72.3%, respectively; p = 0.100).
After propensity-score matching, similar results were also reproduced. Hence, TACE could be
an effective alternative to RFA in terms of OS rates. However, TACE should be confined only to
RFA-difficult cases, given its lower CR and RFS rates and multi-disciplinary approaches are
desirable in decision-making.
Abstract: Radiofrequency ablation (RFA) is a curative treatment for early-stage hepatocellular
carcinoma (HCC) ineligible for surgery or liver transplantation. However, trans-arterial
chemoembolization (TACE) might be an alternative when RFA is contraindicated due to
structural problems. Here, we aimed to compare their long-term outcomes. Treatment-naive
HCC patients fulfilling the Milan criteria who underwent RFA (n = 136) or TACE (n = 268)
were enrolled. Complete response (CR) and 5-year recurrence-free survival (RFS) rates were
higher in the RFA group than in the TACE group (94.1% vs. 71.6% and 35.8% vs. 17.0%,
respectively; both p < 0.001), whereas 5-year overall survival (OS) rates were not significantly
different (65.5% vs. 72.3%, respectively; p = 0.100). Multivariate analysis showed that RFA was
associated with better RFS (adjusted hazard ratio [aHR] 0.628; p = 0.001) than TACE, but not
with better OS (aHR 1.325; p = 0.151). The most common 1st-line treatment after recurrence
were TACE (n = 53), followed by RFA (n = 21) among the RFA group and TACE (n = 150),
followed by RFA (n = 44) among the TACE group. After propensity-score matching, similar
results were reproduced. Hence, TACE could be an effective alternative to RFA in terms of OS
rates. However, TACE should be confined only to RFA-difficult cases, given its lower CR and
RFS rates and multi-disciplinary approaches are desirable in decision-making.
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1. Introduction
Currently, hepatocellular carcinoma (HCC) is a major health problem both in Korea and
worldwide [1–3]. Hepatic resection or orthotopic liver transplantation (OLT) is the preferred curative
treatment modality [4]. However, in the real-world practice, a substantial proportion of HCC patients
are treated with various non-surgical options, primarily owing to tumor burden, the limited hepatic
functional reserves, shortage of organ donors, high morbidities and mortalities associated with surgery,
and patients’ refusals [5–10]. Among the non-surgical options, percutaneous radiofrequency ablation
(RFA) is recommended as the first-line treatment in very-early-stage HCC (single tumor with a
diameter < 2 cm) and as an alternative first-line treatment in early-stage HCC (single tumor size up to
5 cm, or up to three nodules with each having a maximal diameter < 3 cm), because it is less invasive
and more tolerable than hepatic resection [11–13]. However, the rates of post-procedural recurrence
(either local or distant) can be as high as 70% at 5 years, causing significant challenges with respect to
long-term survival among patients treated with RFA [14].
Moreover, when tumors are located in the sub-capsular region, dome, or adjacent to intestinal loops
or the bile duct, RFA is technically not feasible owing to higher risks of bleeding, perforation, or bile
leakage [15]. In such cases, hepatic resection and OLT are also not feasible options. While selective
trans-arterial chemoembolization (TACE) could be a viable alternative, it is primarily optimized
as a palliative treatment for intermediate-to-advanced-stage HCC, despite several retrospective
cohort studies indicating acceptable survival outcomes for patients with treatment-naïve early-stage
HCC [16,17]. Moreover, the baseline tumor characteristics across previous studies on TACE were
somewhat heterogeneous. Therefore, it remains unclear whether TACE and RFA provide a comparable
outcome in early-stage HCC cases.
Here, we aimed to compare the treatment efficacies and outcomes of TACE and RFA as the
first-line modality for treatment-naïve patients with early-stage HCC who fulfilled the Milan criteria
(single tumor size up to 5 cm or up to three nodules ≤ 3 cm; no vascular invasion; and no extrahepatic
spread) by evaluating not only recurrence-free survival (RFS) rate and treatment response, but also the
overall survival (OS) rate.
2. Materials and Methods
2.1. Patients
Treatment-naïve patients with early-stage HCC who underwent RFA or TACE as an initial treatment
at Severance Hospital, Seoul, Korea, between March 2005 and December 2016, were considered eligible
for this study. The diagnosis of HCC was confirmed based on current practice guidelines of the
American Association for the Study of Liver Diseases and the European Association for the Study of
the Liver [4,18–20]. Liver biopsy was performed when diagnosis of HCC was unclear with clinical and
radiological information. The inclusion criteria were as follows: age ≥ 19 years; presence of at least
one uni-dimensional lesion measurable according to the modified response evaluation criteria in solid
tumors (mRECIST) [21]; single tumor sized up to 5 cm or up to three nodules measuring ≤ 3 cm; Eastern
Cooperative Oncology Group performance status of 0 to 2; platelet count ≥ 50×103/µL; and serum
alanine aminotransferase (ALT) levels <10 times the upper limit of normal. The exclusion criteria were
as follows: history of anti-HCC treatment or portal or hepatic vein invasion; lymph node metastasis
or extra-hepatic spread; Child–Pugh class C; any other uncontrolled co-morbidities or malignant
neoplasms; and a prior OLT.
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The patients provided written informed consent for the invasive procedures. The study protocol
was in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by
the institutional review board of Severance Hospital (4-2018-0969).
2.2. Treatment Procedures and Follow-Up
RFA was performed based on the standard protocol of our institution. To assess the feasibility
and applicability of RFA, a planning ultrasound was routinely performed. Then, the patients were
treated percutaneously using an RFA device under ultrasound guidance. The tumor was ablated until
ablation of the entire tumor was achieved. Immediately after RFA, complete ablation was confirmed
using dynamic computed tomography (CT).
TACE was also performed based on the standard protocol of our institution. The femoral artery was
accessed via catheterization under ultrasound guidance. Hepatic angiography was performed to assess
the vascular anatomy, tumor staining, and portal vein thrombosis. TACE was performed by infusion
with a mixture of 5 mL iodized oil contrast medium (Lipiodol; Guerbet, Aulnay-sous-Bois, France)
and 50 mg adriamycin, regardless of patients’ body weight, which was followed by embolization
of the feeding arteries using gelatin sponge particles (Cutanplast; Mascia Bruneili S.p.A., Milano,
Italy). The reduction of adriamycin dosage to 30 mg might be allowed according to the discretion of
intervention radiologists, in case that the deterioration in the liver function after TACE was anticipated.
The overall same procedure was performed for both single and multiple HCCs.
One month after RFA or TACE, laboratory tests including tumor markers, i.e., alpha-fetoprotein
(AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II), as well as imaging studies,
i.e., dynamic CT or magnetic resonance imaging, were performed. Subsequently, the patients were
followed-up every 3 months to monitor the recurrence after RFA or TACE. Treatment response was
evaluated using mRECIST [21]. When the patient did not achieve complete response (CR), additional
treatment was performed until the achievement of CR according to the physicians’ discretion.
2.3. Definitions and Evaluation of Data
The study endpoints were OS, RFS, and radiological response. OS was defined as the interval
between initial treatment and death from any cause. RFS was defined as the period between initial
treatment and radiologically confirmed recurrence, based on follow-up imaging data. Radiological
response was evaluated according to mRECIST 4 weeks after RFA or TACE [21].
2.4. Statistical Analysis
The differences between the RFA and TACE groups were compared using the independent t-test
for continuous data, and the chi-square test or Fisher’s exact test for categorical data. OS and RFS were
estimated using the Kaplan–Meier curve and compared using the log-rank test. To identify the factors
associated with RFS or OS, a Cox regression model was used to calculate the hazard ratio (HR) and
95% confidence interval (CI) for each variable in the univariate and multivariate analysis.
Furthermore, to reduce the effect of selection bias and potential confounders between the RFA
and TACE groups, the propensity score (PS) was calculated using logistic regression, and PS-matching
was performed at a 1:1 ratio using age, male sex, etiology, presence of liver cirrhosis, platelet count,
Child-Pugh class, tumor size (expressed as a sum of each tumor diameter), single tumor, AFP,
and PIVKA-II as adjusted variables.
A p-value less than 0.05 was considered significant. All statistical analyses were performed using
R, version 3.6.0 (the R Foundation for Statistical Computine, Vienna, Austria) with ‘survival’ package,
and SAS (version 9.4, SAS Inc., Cary, NC, USA).
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3. Results
3.1. Patients’ Baseline Characteristics
A total of 404 patients, including 268 in the TACE group and 136 in the RFA group, were finally
enrolled. Patients’ baseline characteristics are summarized in Table 1. The overall median age was
69.3 years, with a predominance of men (73.0%). The most common etiology of HCC was hepatitis
B virus infection (70.3%), followed by hepatitis C virus infection (14.6%). The non-viral etiologies
were as follows; alcohol (n = 28), non-alcoholic steatohepatitis (n = 13), autoimmune liver disease
(n = 1), and others (n = 19). Twenty-two patients were diagnosed as HCC based upon pathological
data and their histological differentiation was as follows: Edmondson grade I (n = 16), grade II (n = 5),
and grade 3 (n = 1).
Table 1. Comparison of baseline clinical characteristics between the two groups before adjustment.
Variables TACE Group (n = 268) RFA Group (n = 136) p-Value
Age, years 69.3 ± 9.0 69.1 ± 10.1 0.840
Male 193 (72.0%) 102 (75.0%) 0.523
Etiology 0.153
HBV 195 (72.8%) 89 (65.4%)
HCV 39 (14.6%) 20 (14.7%)
Non-B, Non-C 34 (12.6%) 27 (19.9%)
Liver cirrhosis 210 (78.4%) 104 (76.5%) 0.667
Child-Pugh class 0.444
A 243 (90.7%) 120 (88.2%)
B 25 (9.3%) 16 (11.8%)
Platelet count, ×103/uL 117 ± 50.9 128 ± 59.9 0.080
Tumor size, cm 2.83 ± 1.11 1.98 ± 0.69 <0.0001
Single tumor 184 (68.7%) 129 (94.9%) <0.001
AFP, ng/mL 181.9 ± 625.3 159.5 ± 494.4 0.695
PIVKA-II 0.056
<1000 mAU/mL 260 (97.01%) 136 (100%)
≥1000 mAU/mL 8 (2.99%) 0 (0%)
Abbreviations: TACE, trans-arterial chemoembolization; RFA, radiofrequency ablation; HBV, hepatitis B virus;
HCV, hepatitis C virus; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II.
Most patients had a single tumor (77.5%), liver cirrhosis (77.7%), and Child-Pugh class A (89.9%).
On comparing the baseline clinical characteristics between the two groups, the TACE group was
found to have a larger average tumor size (expressed as a sum of each tumor diameter) (2.83 ± 1.11
vs. 1.98 ± 0.69 cm, respectively; p < 0.001) and lower proportion of single tumors than the RFA group
(68.7% vs. 94.9%, respectively; p < 0.001). However, there were no significant differences in other
variables between the two groups.
3.2. Radiological and Biological Treatment Response for the Entire Cohort
Table 2 shows the radiological response, which was assessed through mRECIST 4 weeks after
treatment [18]. Figures S1 and S2 showed the representative images before RFA or TACE and CR
cases after treatment. Evidently, the RFA group had a higher proportion of CR (94.1% vs. 71.7%)
and objective response (sum of CR and partial response) (97.8% vs. 87.7%) than the TACE group
(both p < 0.001).
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Table 2. Radiological response according to the treatment modality in the entire population.
Radiological Response TACE Group (n = 268) RFA Group (n = 136) p-Value
<0.001
Complete response 192 (71.64%) 128 (94.12%)
Partial response 43 (16.04%) 5 (3.68%)
Stable disease 29 (10.82%) 2 (1.47%)
Progressive disease 4 (1.49%) 1 (0.74%)
Abbreviations: TACE, trans-arterial chemoembolization; RFA, radiofrequency ablation.
Among 388 patients where both AFP and PIVKA-II levels 4 weeks after treatment are available,
patients with an objective response are more likely to have an AFP response (defined as≥ 50% reduction
from baseline) than those without (36.2% vs. 14.7%, respectively; p = 0.013). However, in terms of
PIVKA-II response (also defined as ≥ 50% reduction from baseline), there exists only a trend toward
the higher biological response in those with objective response, compared to those without (30.2% vs.
20.6%, respectively; p = 0.239) (Table S1).
3.3. Comparison of Survival Outcomes between the Two Groups for the Entire Cohort
The RFS in the two groups was significantly different (Figure 1a; p < 0.001). The RFA group
showed a significantly better 5-year RFS rate (35.8% vs. 17.0%; HR 0.560, 95% CI 0.432–0.726; p < 0.001)
than the TACE group; the cumulative probabilities of recurrence at 1, 3, and 5 years in the TACE group
were 42.8%, 73.9%, and 83.0%, respectively. In contrast, those in the RFA group were 24.4%, 50.7%,
and 64.2%, respectively (Figure 1a).
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Conversely, OS was not significantly different between the two gr ups (Figure 1b; p = 0.100).
The 5-year OS rate in the RFA group was 65.5%, compared with 72.3% in the TACE group (HR 1.330,
95% CI 0.910–1.943; p = 0.141); the cumulative probabilities of death at 1, 3, and 5 years in the TACE
group were 4.1%, 15.6%, and 27.7%, respectively. In contrast, those in the RFA group were 6.62%,
20.6%, and 34.5%, respectively (Figure 1b).
3.4. Estimation of Predictors for Recurrence and Death in the Entire Cohort
Univariate and multivariate Cox regression analyses were performed to determine independent
prognostic factors for recurrence and death. Univariate predictors were included in the multivariate
analysis to assess the independent associations between the variables and clinical outcomes.
RFA (vs. TACE) was associated with a lower probability of recurrence (adjusted HR 0.628, 95% CI
0.473–0.834, p = 0.001]); however, other variables did not have independent associations with recurrence
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(Table S2). In contrast, age, liver cirrhosis, and Child-Pugh class B were significant univariate predictors
for death (all p < 0.05). After adjusting for these variables, we found that RFA (vs. TACE) was not
associated with death (adjusted HR 1.325, 95% CI 0.902–1.948; p = 0.151). Finally, age (adjusted HR
1.042, 95% CI 1.019–1.067; p < 0.001) and Child-Pugh class B (adjusted HR 2.167, 95% CI 1.291–3.636;
p = 0.003) were revealed to be independent predictors of death based on multivariate analysis (Table S3).
3.5. Subsequent Treatments after Recurrence
The first-line treatment modalities against the recurred lesion were as follows; TACE (n = 53),
followed by RFA (n = 21), best supportive care (n = 3), surgical resection or OLT (n = 2),
and systemic chemotherapy (n = 1) among the RFA group and TACE (n = 150), followed by RFA
(n = 44), best supportive care (n = 8), surgical resection or OLT (n = 5), liver-directed concurrent
chemoradiotherapy (n = 2), systemic chemotherapy (n = 2), and external beam radiotherapy (n = 1)
among the TACE group.
During the follow-up, 16 patients among the RFA group experienced extra-hepatic spread (i.e., M1)
and/or lymph node metastasis (i.e., N1), while 47 among the TACE group did.
Furthermore, as their first-line systemic chemotherapy during the follow-up, 13 and
two patients among the RFA group were treated with sorafenib and lenvatinib, whereas 33,
one, and one patients among the TACE group were treated with sorafenib, lenvatinib, and cytotoxic
chemotherapy, respectively.
3.6. Analyses in the PS-Matched Cohort
Among a total of 404 patients, PS-matching provided 122 pairs. The baseline clinical characteristics
of the patients after PS-matching are summarized in Table 3, which also shows the acceptable balance
between the TACE and RFA groups (all p > 0.05). Table 4 shows the radiological response in the
PS-matched cohort according to the treatment modality used (TACE vs. RFA). We found that the RFA
group had a higher proportion of CR (94.3% vs. 73.8%) and objective response (97.6% vs. 85.3%) than
the TACE group (both p < 0.001), even after PS-matching.
Table 3. Comparison of baseline clinical characteristics between the two groups after adjustment using
propensity score (PS)-matching.
Variables TACE Group (n = 122) RFA Group (n = 122) p-Value
Age, years 68.8 ± 9.1 69.0 ± 9.8 0.840
Male 85 (69.7%) 90 (73.8%) 0.435
Etiology 0.599
HBV 82 (67.2%) 82 (67.2%)
HCV 19 (15.6%) 17 (13.9%)
Non-B, Non-C 21 (17.2%) 23 (18.9%)
Liver cirrhosis 95 (77.9%) 95 (77.9%) >0.999
Child-Pugh class 0.706
A 109 (89.3%) 107 (87.7%)
B 13 (10.7%) 15 (12.3%)
Platelet count, ×103/uL 122 ± 54.2 122.4 ± 58.7 0.922
Tumor size, cm 2.03 ± 0.75 2.03 ± 0.70 0.9943
Single tumor 117 (95.9%) 115 (94.3%) 0.480
AFP, ng/mL 139.1 ± 471.8 155.5 ± 484.0 0.780
PIVKA-II >0.9999
<1000 mAU/mL 122 (100.00%) 122 (100.00%)
≥1000 mAU/mL 0 (0.00%) 0 (0.00%)
Abbreviations: PS, propensity score; TACE, trans-arterial chemoembolization; RFA, radiofrequency ablation;
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin
K absence-II.
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Table 4. Radiological response according to the treatment modality after adjustment through
PS-matching.
Radiological Response TACE Group (n = 122) RFA Group (n = 122) p-Value
0.001
Complete response 90 (73.77%) 115 (94.26%)
Partial response 14 (11.48%) 4 (3.28%)
Stable disease 16 (13.11%) 2 (1.64%)
Progressive disease 2 (1.64%) 1 (0.82%)
Abbreviations: PS, propensity score; TACE, trans-arterial chemoembolization; RFA, radiofrequency ablation.
Similar results were also reproduced for recurrence; the RFA group had a better 5-year RFS rate
than the TACE group (Figure 2a; 36.0% vs. 20.1%; p = 0.006). The cumulative probabilities of recurrence
at 1, 3, and 5 years in the TACE group were 43.9%, 71.7%, and 79.9%, respectively, whereas those in the
RFA group were 22.2%, 49.1%, and 64.0%, respectively (Figure 2a).
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In terms of deaths, there was no significant difference in the 5-year OS rate between the TACE
and RFA groups (Figure 2b; 73.1% vs. 65.9%; p = 0.07). The cumulative probabilities of death at 1, 3,
and 5 years in the TACE group were 4.9%, 15.7%, and 26.9%, respectively, whereas those in the RFA
group were 7.4%, 19.7%, and 34.1%, respectively (Figure 2b).
4. Discussion
For patients with unresectable HCC who fulfill the Milan criteria, OLT and RFA are generally
accepted as the principal choices with a curative aim. Among these, OLT is largely limited by the donor
organ shortage, especially in the Korea, where living donor liver transplantation currently accounts for
more than 80% of cases. Although RFA is considered the treatment of choice for early-stage HCC in the
real-word practice, a substantial number of HCC patients still undergo TACE as the first-line treatment
for tumor control and survival prolongation [22]. Here, we assessed the survival benefit among
early-stage HCC patients who underwent TACE instead of RFA for technical reasons. This study has
several strengths. First, it had a relatively large sample size (n = 404), in comparison with that in
previous studies [16,23,24], as well as a sufficient number of events during the long-term follow-up,
which provided significant statistical power. Second, our study results were consistently reproduced
through multivariate Cox regression and PS-matching analyses.
We found no significant difference between the TACE and RFA groups with regard to the 5-year
OS rate in early-stage HCC patients. In other words, when RFA is not technically feasible, patients
with early-stage HCC, including those with a single tumor, can achieve the same therapeutic benefit in
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terms of OS through TACE [25], although, as expected, the TACE group had a poorer CR and 5-year
RFS rate than the RFA group.
The inferior CR and 5-year RFS rates with TACE are consistent with theoretical perspectives;
RFA is performed through thermal ablation of the tumor itself, whereas TACE is performed by
injecting chemotherapeutic agents in tumor feeding vessels. Even though arteries are blocked by
TACE, tumors attempt to develop new vessels through angiogenesis to receive blood supply from the
hepatic portal vein [26,27]. Moreover, well-differentiated parts of HCC tumors are often fed by portal
veins [28], also leading to a relatively lower local control rate with TACE. This discrepancy between
analyses of death and recurrence according to the treatment modality might, in part, be explained by
several hypotheses. First, it is generally recognized that most patients with HCC encounter multiple
treatment failure events, not only at the treatment site, but also at other intrahepatic sites, owing to de
novo carcinogenesis. Therefore, subsequent treatments, such as repeated RFA, TACE, external beam
radiation therapy, or other systemic therapy, are commonly performed after initial single loco-regional
treatment (LRT). Second, the survival of patients with HCC is not only strongly associated with tumor
factors, but also with the severity of underlying liver dysfunction, evidenced by the observation that
age and Child-Pugh class were independent predictors of OS in the present study. Consequently,
the higher CR rate and lower recurrence rate achieved with RFA may not directly translate into better
long-term OS benefits.
Nevertheless, TACE cannot be equated with RFA while choosing an optimal treatment strategy
for early-stage HCC. Our results indicated that RFA is more advantageous from the perspectives of
medical expenses and quality of life, since it has better CR and RFS rates than TACE. Furthermore,
for patients with anatomical problems, i.e., presence of bland portal vein thrombosis or arterio-portal
shunt, and with Child-Pugh class B, TACE, as an alternative treatment modality to RFA, might have
a limited therapeutic performance, primarily owing to risk of deterioration in the liver function
after treatment. Therefore, TACE should be confined only to RFA-difficult cases. A well-designed
randomized controlled trial would be ideal to obtain robust evidence on the therapeutic benefits of
TACE and RFA. However, this is not completely feasible, primarily owing to the current concept that
TACE is essentially one of the palliative treatment options for large and/or multinodular HCCs and the
resultant ethical concerns. In the same context, in our study, the RFA group tended to have a smaller
tumor size and a higher proportion of single tumors, indicating that most hepatologists prefer RFA to
TACE for smaller and solitary tumors, consistent with the requisite guidelines [4].
Additionally, several studies have implied that a radiologic response to LRT is an important
factor for predicting the patients’ long-term survival outcome [29,30]. Particularly, for those treated
with TACE, the achievement of CR after the first TACE is of paramount significance for maintaining
long-term OS [31]. As the effect of the initial TACE is the most important for improving OS, and multiple
TACE sessions may have unfavorable effects on liver function, during the initial TACE procedure,
maximizing total tumor necrosis might be preferable in practice, as far as permitted by hepatic
function [32]. Furthermore, considering that angiogenic factors associated with poor prognosis, such as
serum vascular endothelial growth factor and hypoxia-inducible factor-1 alpha, tend to increase in
suboptimal responders after TACE [33], further efforts to achieve CR would also be required. Therefore,
combination therapy with RFA, external beam radiotherapy, or adjuvant targeted therapy along with
an initial cycle of TACE, if necessary, could also be considered to achieve complete necrosis. Actually,
substantial numbers of patients among the RFA group were subsequently treated using TACE for
recurred HCC and those in the TACE group were also treated using subsequent RFA. It indicates that
multi-disciplinary approaches for the recurred lesion, as well as an initial treatment modality, should
be important in RFA-difficult patients in order to prolong their survival outcomes.
There are several limitations to this study. First, it was a retrospective study conducted in a
single institute, which may introduce selection bias, particularly in terms of patients’ demographic
characteristics and treatment allocation. However, to overcome this, we performed various statistical
adjustments, confirming that similar patterns of results were consistently reproduced. A multi-center,
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prospective randomized study is needed, although such a study is unlikely to be conducted in the
near future. Therefore, this observational study has considerable scientific value. Second, recently,
LRTs other than TACE have become popular as an alternative to RFA. For example, stereotactic body
radiation therapy might provide similar or better local control rates than RFA in some cases [34],
and microwave ablation could be more advantageous in terms of increased ablation volumes, sustained
tissue temperatures, shorter duration of therapy, and susceptibility to the heat sink effect for HCCs
located adjacent to vascular structures [35]. Thus, to select personalized treatment options, further
studies are required to assess the short- and long-term efficacy of each modality and risk factors for
treatment failure. Finally, our results might not be generalizable to the full spectrum of HCC patients,
as chronic HBV infection was the most predominant etiology among our study population.
5. Conclusions
In conclusion, TACE could be an effective alternative to RFA in terms of the 5-year OS rate
for early-stage HCC, provided that appropriate subsequent treatments are administered. However,
TACE should be confined only to RFA-difficult cases, given its lower CR and RFS rates and risk of
deterioration in the liver function after treatment, as compared with RFA.
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